Local control of metastatic lung tumors treated with SBRT of 48 Gy in four fractions: In comparison with primary lung cancer

Japanese Journal of Clinical Oncology

Volumn 40, Issue 2, 2010, Pages 125-129

  Hamamoto, Yasushi ^a   Kataoka, Masaaki ^a   Yamashita, Motohiro ^a   Shinkai, Tetsu ^a   Kubo, Yoshiro ^a   Sugawara, Yoshifumi ^a   Inoue, Takeshi ^a   Sakai, Shinya ^a   Aono, Shoji ^a   Takahashi, Tadaaki ^a   Semba, Takatoshi ^a   Uwatsu, Kotaro ^a  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

Lung carcinoma; Neoplasm metastasis; Stereotactic body radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; HUMAN; JAPAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; RADIATION DOSE FRACTIONATION; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; SURVIVAL TIME; THYMUS CANCER; UTERINE CERVIX CANCER; COLORECTAL TUMOR; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; RADIATION DOSE; RADIATION RESPONSE; RADIOSURGERY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOSURGERY; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77449129881     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp129     Document Type: Article

References (11)

1. Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004;101:1623-31.
2. Wulf J, Haedinger U, Oppitz U, Thiele W, Mueller G, Flentje M. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys 2004;60:186-96.
3. Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005;63:1427-31.
4. Zimmermann FB, Geinitz H, Schill S, Grosu A, Schratzenstaller U, Molls M, et al. Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer. Lung Cancer 2005;48:107-14.
5. Kyle E, Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 2009;27:1579-84.
6. Norihisa Y, Nagata Y, Takayama K, Matsuo Y, Sakamoto T, Sakamoto M, et al. Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys 2008;72:398-403.
7. Milano MT, Katz AW, Schell MC, Philip A, Okunieff P. Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2008;72:1516-22.
8. Kim MS, Yoo SY, Cho CK, Yoo HJ, Choi CW, Seo YS, et al. Stereotactic body radiation therapy using three fractions for isolated lung recurrence from colorectal cancer. Oncology 2009;76:212-9.
9. The International Registry of Lung Metastases. Long-term results of metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 1997;113:37-49.
10. Milano MT, Karz AW, Muhs AG, Philip A, Buchholz DJ, Schell MC, et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 2008;112:650-8.
11. McCammon R, Schefter TE, Gaspar LE, Zaemisch R, Gravdahl D, Kavanagh B. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2009;73:112-8.